Full-Time

Events Platform Business Partner

Deadline 8/24/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, MBA

Category
Data & Analytics (1)
Required Skills
Agile
CRM
Web Development
Data Governance

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A bachelor's degree from an accredited four-year college or university is required.
  • Seven or more years of progressive events platform and customer relationship management operations experience with demonstrated leadership are required.
  • Seven or more years of experience in biotechnology or pharmaceuticals are required.
  • Strong English communication skills and the ability to engage and align diverse stakeholders across geographies and functions are required.
Responsibilities
  • Lead the strategic vision and roadmap for Events and Congresses platform capabilities across OneCRM US, ensuring alignment with enterprise customer relationship management standards and business priorities.
  • Serve as the technical authority for Veeva Events and Congresses, influencing platform architecture decisions and integration strategies across the OneCRM US ecosystem.
  • Design and implement scalable event platform solutions supporting multi-brand Speaker Meetings, Displays, Product Theaters, Scientific Education Programs, and Speaker Trainings across multiple markets and business units.
  • Drive enterprise-wide data governance for events data, establishing standards and frameworks for transparency, compliance, and data integrity across all event types and downstream systems.
  • Architect end-to-end event platform frameworks and processes, including topic management, speaker profiles, budgets, and nomination tools, that scale with organizational growth and platform evolution.
  • Lead and mentor the events platform operations team, providing technical guidance, knowledge transfer, and career development support.
  • Influence technical decisions across requirements gathering, system enhancements, and user acceptance testing for major platform initiatives, ensuring solutions are scalable, compliant, and fit for enterprise purposes.
  • Shape the long-term roadmap for Events and Congresses platform evolution and integration with downstream systems, including iCare, transparency, fair market value, GRF, and contracting.
  • Lead change management efforts for platform enhancements and system evolution, driving adoption and alignment across field teams, Field Engagement Management, and business stakeholders.
  • Drive capability building across the broader customer relationship management community through structured knowledge sharing, best practice development, and train-the-trainer programs.
  • Partner with Field Engagement Management, Sales, Marketing, Medical, Compliance, and Business Operations to influence event platform strategy and ensure the platform meets evolving business requirements.
  • Lead transformation of events operational processes, establishing performance measurement frameworks and continuous improvement approaches that drive platform excellence.
  • Investigate and remediate escalated inquiries, applying technical expertise to resolve complex issues and prevent recurrence through systemic process improvements.
  • Drive cross-functional collaboration across partner Go-to-Market Capabilities US teams, ensuring event platform strategies are integrated with broader customer relationship management initiatives and enterprise data standards.
Desired Qualifications
  • A Project Management master's degree or Master of Business Administration is preferred.
  • Experience leading technical teams and driving strategic platform initiatives across enterprise-scale programs is preferred.
  • Experience in solution architecture for event management platforms and customer relationship management systems is preferred.
  • Advanced expertise in data governance, compliance requirements including PhRMA guidelines, and data integrity across events and transparency reporting is preferred.
  • Advanced skills in managing senior stakeholder relationships across business units and multiple launch projects are preferred.
  • Experience influencing enterprise-wide platform strategy and operational approaches is preferred.
  • Strong knowledge and experience with Veeva Events and Congresses, Agile processes, and event management systems are preferred.
  • Deep understanding of the events ecosystem, including transparency, fair market value, GRF, contracting, and field engagement integration, is preferred.
  • Experience working and thriving in a matrix environment is preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026: Sanofi raised 2026 sales guidance to about 10% constant-currency growth.
  • July 30, 2026: Dupixent grew 37.6%; launches rose 48.3%, led by Ayvakit and Sarclisa.
  • June 23, 2026: Wayrilz and Cenrifki approvals expanded Sanofi’s rare-disease and multiple-sclerosis franchises.

What critics are saying

  • June 26, 2026: European Commission probed Sanofi for anti-competitive flu-vaccine disparagement in Germany and France.
  • January 2026: FDA rejected tolebrutinib over severe liver injury, blocking Sanofi’s neurology comeback.
  • July 15, 2026: Sanofi sued Pfizer and Moderna, inviting countersuits and expensive patent warfare.

What makes Sanofi unique

  • August 2026: Dupixent topped €5.1 billion quarterly sales, proving platform scale.
  • July 10, 2026: Sarclisa Escena became first anticancer therapy delivered via on-body injector.
  • July 30, 2026: Sanofi’s pipeline produced seven approvals across immunology, oncology, neurology, and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.

Yahoo Finance
Jun 30th, 2026
3 high-yielding dividend stocks hit 52-week lows: Sanofi, AT&T, and Vici Properties

AT&T shares have fallen 17% in 2026, hitting new lows this week, amid concerns about SpaceX expanding its Starlink mobile service. The telecom stock's decline comes despite its stable business and typically reliable long-term growth prospects. Investors worry increased competition from Starlink could further limit AT&T's growth opportunities. However, some analysts believe the market may be overreacting to the threat. The company maintains strong fundamentals with steady cash flow supporting its dividend payments. AT&T's current challenges have pushed its dividend yield higher, potentially making it attractive for income-focused investors willing to overlook near-term competitive pressures. Sanofi and Vici Properties also recently hit 52-week lows whilst offering high dividend yields above 5%, presenting potential opportunities for bargain hunters seeking quality dividend stocks at reduced valuations.

Yahoo Finance
Jun 27th, 2026
Deutsche Bank cuts Sanofi price target to $107 from $113, maintains buy rating

Deutsche Bank has cut its price target on Sanofi to €95 from €100 whilst maintaining a Buy rating on the shares. The pharmaceutical company reported strong fiscal Q1 2026 results, with sales growing 13.6% at constant exchange rates and business earnings per share reaching €1.88. Sanofi's newly launched pharmaceuticals drove performance, with sales rising 49.6% to €1.2 billion, led by Ayvakit, ALTUVIIIO and Sarclisa. Dupixent sales grew 30.8% to €4.2 billion, whilst vaccine sales increased 2.1% to €1.3 billion. Research and development expenses rose 1.5% to €1.7 billion, whilst selling and general expenses climbed 11.6% to €2.3 billion, primarily reflecting recent acquisitions. Sanofi operates through three segments: Pharmaceuticals, Consumer Healthcare and Vaccines.